Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

DXCM earnings call for the period ending December 31, 2024.

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...